Suppr超能文献

抗毒蕈碱药物、5型磷酸二酯酶抑制剂及植物疗法在男性下尿路症状治疗中的应用

The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men.

作者信息

Ng Kok Kit, Ng Foo Cheong

机构信息

Department of Urology, Changi General Hospital, Singapore.

出版信息

Asian J Urol. 2017 Jul;4(3):191-194. doi: 10.1016/j.ajur.2017.05.002. Epub 2017 May 26.

Abstract

Besides the mainstay of α-blockers and 5α-reductase inhibitors, other forms of medical therapy complete the armamentarium in the treatment of lower urinary tract symptoms (LUTS) in men. These treatments can target specific symptoms as well as associated symptoms that would affect the quality of life of the patients. Many patients are bothered by storage symptoms, more so than the voiding symptoms. Antimuscarinics are efficacious and safe, provided the patients do not have high post void residual urine. Many patients with LUTS also have erectile dysfunction, and phosphodiesterase type V inhibitors are effective in relieving both LUTS as well as erectile dysfunction for such patients. Phytotherapy provides a popular and safe treatment for LUTS, however, the efficacy of the treatment has not been proven in well conducted prospective randomized controlled studies.

摘要

除了α受体阻滞剂和5α还原酶抑制剂这两种主要药物外,其他形式的药物治疗也完善了男性下尿路症状(LUTS)的治疗手段。这些治疗方法可以针对特定症状以及会影响患者生活质量的相关症状。许多患者受储尿期症状困扰的程度超过排尿期症状。抗胆碱能药物有效且安全,前提是患者没有高残余尿量。许多LUTS患者还伴有勃起功能障碍,对于这类患者,5型磷酸二酯酶抑制剂在缓解LUTS和勃起功能障碍方面均有效。植物疗法为LUTS提供了一种常用且安全的治疗方法,然而,其疗效尚未在精心设计的前瞻性随机对照研究中得到证实。

相似文献

1
The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men.
Asian J Urol. 2017 Jul;4(3):191-194. doi: 10.1016/j.ajur.2017.05.002. Epub 2017 May 26.
3
Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
Drugs Today (Barc). 2016 Sep;52(9):501-517. doi: 10.1358/dot.2016.52.9.2525739.
7
Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
J Urol. 2008 Jan;179(1):220-5. doi: 10.1016/j.juro.2007.08.152. Epub 2007 Nov 14.
9
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.
10
Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Int J Urol. 2013 Jan;20(1):28-39. doi: 10.1111/iju.12008. Epub 2012 Nov 28.

引用本文的文献

3
Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Curr Med Res Opin. 2021 Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899. Epub 2021 May 13.
4
Erectile Dysfunction and Lower Urinary Tract Symptoms.
Curr Urol Rep. 2018 Jun 1;19(8):61. doi: 10.1007/s11934-018-0817-9.
5
Current consensus and controversies on male LUTS/BPH (part one).
Asian J Urol. 2017 Jul;4(3):137. doi: 10.1016/j.ajur.2017.06.005. Epub 2017 Jun 15.

本文引用的文献

1
Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.
Urology. 2013 May;81(5):1030-3. doi: 10.1016/j.urology.2013.01.018. Epub 2013 Mar 16.
2
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.01.018. Epub 2013 Jan 25.
5
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
J Sex Med. 2010 Jan;7(1 Pt 1):59-69. doi: 10.1111/j.1743-6109.2009.01511.x. Epub 2009 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验